TrialScope is part of Informa Pharma Intelligence, a division of Informa Business Intelligence, Inc. (IBI). IBI is a wholly-owned subsidiary of Informa PLC.

This is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

Politicizing the Pandemic: What are the Consequences of Trump’s Rhetoric?


October 28, 2020

 Edit with ElementorSwitch to draftPreviewUpdate▲ Add title

As seen on Pharmaceutical Technology – Posted Oct. 28, 2020 – Original Article

Oct. 28, 2020 | President Trump’s handling of the COVID-19 outbreak in the U.S. has been widely criticized. Over the past seven months, the president has spread misinformation, undermined scientific experts and institutions and placed political pressure on pharma companies to accelerate their vaccine development.

Thomas Wicks, chief strategy officer for TrialScope, weighs in on what, if any, implications these actions have had for public trust of both COVID-19 vaccines and the regulators that will decide whether to approve them.

Continued on Pharmaceutical Technology